close
  • home Home

  • linked_services Solutions keyboard_arrow_down

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

  • mail Contact

  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu

The RIQAS Therapeutic Drug EQA programme is designed to monitor the performance of an impressive 18 therapeutic drugs. Weighed in values are reported for each parameter.

Key Benefits

Lyophilised material for enhanced stability

Submit results and view reports online via Riqas.com

Worlds largest EQA scheme ensuring peer groups are maximised

Bi-Weekly reporting for early identification of test system errors

Cycle Starts - March/September 2026

Accredited to ISO/IEC 17043:2023

Get in touch to discover more

To find out more about RIQAS EQA or to get in touch with your local Randox Representative, enquire now.

DescriptionFrequencySizeCat No
Therapeutic DrugsBi-Weekly12 x 5 mlRQ9111

Parameters

  • Amikacin
  • Gentamicin
  • Primidone
  • Caffeine
  • Lithium
  • Salicylic Acid
  • Carbamazepine
  • Methotrexate
  • Theophylline
  • Ciclosporin
  • Paracetamol (Acetaminophen)
  • Tobramycin
  • Digoxin
  • Phenobarbital
  • Valproic Acid
  • Ethosuximide
  • Phenytoin
  • Vancomycin

Please note, product availability may vary country to country.

Related RIQAS EQA Programmes

General Clinical Chemistry

Immunoassay

Immunoassay Speciality 1

Acusera QC
Complete QC Solutions for Results you Can Trust
RIQAS Brochure
Randox International Quality Assessment Scheme
QCMD
QCMD EQA/PT Schemes for Molecular Infectious Disease Testing.